Clinical Trials Logo

Targeted Molecular Therapy clinical trials

View clinical trials related to Targeted Molecular Therapy.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05177666 Not yet recruiting - Safety Clinical Trials

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

Start date: December 30, 2021
Phase:
Study type: Observational

This is a prospective registration study for patients with advanced refractory solid tumors. Patients who meet the eligibility criteria will be included to participate in the study, and baseline information to be collected after signed informed consent. Patients will choose for themselves whether to carry out targeted therapy or other appropriate treatment methods. And we plan to follow up for at least 12 months or until disease progression or death.

NCT ID: NCT02688491 Not yet recruiting - Renal Neoplasms Clinical Trials

A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

Start date: July 2016
Phase: N/A
Study type: Interventional

Whether patients with stage III clear cell renal cell carcinoma(ccRCC) should receive adjuvant targeted therapy or not is still on debate. The investigators invented a assay consisting of 5 CpGs: cg00396667(PITX1), cg18815943 (FOXE3), cg03890877(TWF2), cg07611000 (EHBP1L1)and cg14391855(RIN1)that was successfully categorise patients with stage III clear cell renal cell carcinoma into high-risk and low-risk groups with Harzard Ratio(HR) of 4.93. Here the investigators randomly assign assay-defined high risk patients of locally advanced ccRCC into adjuvant targeted therapy group and observation group.Disease free survival and overall survival are the end points of observation.